Biopharmaceutical company Genaera Corporation has commenced a multi-center phase II clinical trial to explore the efficacy and safety of higher doses of its investigational drug Evizon for the treatment of the eye disease, wet age-related macular degeneration.
The study is designed to evaluate up to 140 patients with wet age-related macular degeneration (AMD) treated with Evizon at four dose levels of 40mg, 80mg, 120mg and 160mg over a 20 week period.
There is a significant medical need for a drug that treats wet AMD in both eyes simultaneously, while avoiding the complications of intravitreal injections.
Source: Pharmaceutical-Business-Review.
Filed under Eye Treatment, Macular Degeneration | Tags: eye | Comment Below
Related?
Dry age-related macular degeneration (AMD) can be treated by Acucela's visual cycle modulator ACU-4429June 24th, 2009 Acucela Inc. is a clinical-stage biotechnology company, presently focusing on visual cycle modulation (VCM) to develop new methods for treating blinding eye diseases that affect tens of millions of people worldwide.
Dry Age Related Macular Degenetation (AMD) drug shows positive result in phase 2 trialMarch 28th, 2009 NT-501, the lead product candidate of Neurotech Pharmaceutisals, inc., have successfully slowed down the loss of vision in a Phase 2 clinical trial, in patients suffering from macular degeneration along with geographic atrophy(GA). GA is a condition that destroys sharp central vision and causes serious vision loss to one or both eyes.
FDA offers single medical device for treating two types of eye diseaseSeptember 11th, 2008 Now there is a good news for the patients suffering from age-related macular degeneration and retinitis pigmentosa as last week, the U.S. Food and Drug Administration has tracked a novel treatment "a capsule" which helps in protecting vision during these two diseases.
Macular Health vitamin supplement is a new hope for AMD patients: Study confirmsApril 22nd, 2009 Very recently retina specialists at at the Callahan Eye Foundation Hospital at the University of Alabama Birmingham have released the result of second phase of the Multifocal Electroretinogram (MERG) study of age-related macular degeneration patients who were placed on supplemental vitamins, minerals and carotenoids - a combination also known as Macular Health. Macular Health is a unique vitamin supplement that slows vision loss due to age-related macular degeneration (AMD) and reduces the risk of total blindness.
Phase II Clinical Trial of Mifepristone an Eye Drop Treatment for Steroid Associated Elevated Intraocular PressureSeptember 27th, 2006 Global bio-nanotech company pSivida Limited (NASDAQ:PSDV) (ASX:PSD) (Xetra:PSI) today announced the initiation of a Phase II clinical trial of Mifepristone (otherwise known as RU486) as an eye drop treatment for steroid associated elevated intraocular pressure (IOP). The investigator-sponsored trial will involve up to 45 patients in the United States.
Brand New Treatment For Macular DegenerationJuly 8th, 2006 It's the leading cause of blindness in people over the age of 50 and in our Healthy Living report a brand new treatment for Macular Degeneration that some are calling a miracle. Margie Puslipher suffers from Macular Degeneration and was on the verge of blindness.
Hope for Age Related Macular Degeneration with LucentisDecember 31st, 2005 Genentech Inc. has applied for U.S.
Age Related Macular Degeneration May be Prevented with MacugenOctober 8th, 2005 Age-related macular degeneration (AMD) is the leading cause of blindness in older patients in US and the developed world. Pegaptanib sodium (Macugen) is a new treatment for exudative AMD, and has been shown to stabilize vision in approximately 70 percent of cases.
